Supernus Pharmaceuticals

Supernus Pharmaceauticals_Fastest Growing Companies 2018
Courtesy of Supernus Pharmaceauticals
  • Previous Rank
  • Revenue 3 Yr Annual Growth Rate
  • Revenue 3 Yr Growth Rank
  • EPS 3 Yr Annual Growth Rate
  • EPS 3 Yr Growth Rank
  • Total Return 3 Yr Annual Rate
  • Total Return 3 Yr Rank

Supernus Pharmaceuticals is tackling what is, perhaps, the most difficult project in the life sciences sector—treating the diseases that afflict our brains, including epilepsy and migraines. In the second quarter of 2018, the firm’s revenues ballooned by more than 30% to $99.5 million, driven by greater sales of flagship drugs Oxtellar XR and Trokendi XR. The company’s latest earnings figures fell a bit short of Wall Street expectations, but that may not be of much concern given how hot the stock has been over the past five years: It has provided shareholders with a stunning 571% return.

Company Information

LocationRockville, Md.
SectorHealth Care
Current Streak-
Years on List1
CEOJack Khattar

Revenue, Net Income

Revenue past four quarters ($M)$335
Net Income past four quarters ($M)$73

Growth Rates and Ranks

Revenue 3 Yr Growth Rank19
Revenue 3 Yr Annual Growth Rate46%
EPS 3 Yr Growth Rank5
EPS 3 Yr Annual Growth Rate154%
Total Return 3 Yr Rank8
Total Return 3 Yr Annual Rate52%
Beat S&P 500 (11.9%)yes
P/E Ratio29